Get the Stockscreener App
151.16
1.07%
1.60
After Hours:
151.16
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $151.16, with a volume of 2.08M.
It is up +1.07% in the last 24 hours and up +4.85% over the past month.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
See More
Previous Close:
$149.56
Open:
$151.78
24h Volume:
2.08M
Relative Volume:
0.75
Market Cap:
$41.65B
Revenue:
$21.37B
Net Income/Loss:
$1.41B
P/E Ratio:
38.33
EPS:
3.9437
Net Cash Flow:
$3.07B
1W Performance:
+2.75%
1M Performance:
+4.85%
6M Performance:
-22.07%
1Y Performance:
-11.62%
1-Day Range:
$150.70
$153.24
1-Week Range:
$143.13
$153.24
52-Week Range:
$141.82
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
151.16 | 41.21B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
422.06 | 148.33B | 10.58B | 3.00B | 2.83B | 8.2437 |
ALC
Alcon Inc
|
66.81 | 32.47B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
196.04 | 28.19B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
33.61 | 29.13B | 29.14B | 1.07B | 1.05B | 1.1956 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Goldman | Neutral |
| Feb-10-26 | Resumed | Barclays | Overweight |
| Feb-03-26 | Resumed | Citigroup | Buy |
| Sep-25-25 | Initiated | RBC Capital Mkts | Sector Perform |
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait” - Insider Monkey
Becton Dickinson earnings loom as investors eye post-divestiture growth By Investing.com - Investing.com
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Deals tracker: Tennessee senior care operator spends $50M for 5 facilities - Modern Healthcare
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Becton Dickinson chairman, CEO Thomas E. Polen Jr. sells $404k in shares - Investing.com UK
Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider - GlobeNewswire Inc.
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co stock (US0758871091): Norges Bank stake highlights interest after recent earni - AD HOC NEWS
Becton, Dickinson And Company (BDX) Stock Analysis: Exploring A 23% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $163 - 富途牛牛
Becton Dickinson resumes U.S. shipments of ChloraPrep after additional testing - TradingView
Here’s Hinde Group’s Updates on Becton, Dickinson and Company (BDX) - Insider Monkey
Piper Sandler Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $161 - Moomoo
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Becton Dickinson EVP Michael Feld sells $11,051 in stock - Investing.com UK
Becton Dickinson EVP Michael Feld sells $11,051 in stock By Investing.com - Investing.com UK
Goldman Sachs Adjusts PT on Becton, Dickinson and Co. to $150 From $156, Maintains Neutral Rating - Moomoo
Becton, Dickinson And Company (BDX): Evaluating Growth Potential With A 24% Upside - DirectorsTalk Interviews
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story - simplywall.st
Becton, Dickinson & Co. Faces Valuation Shift Amid Declining Stock Returns and High Debt - Markets Mojo
BD Delivers Kidney Stone Care for Urology Teams with the Elyra Thulium Fiber Laser System - Finviz
New BD laser targets smoother, quieter kidney stone care procedures - Stock Titan
Becton Dickinson and Co stock (US0758871091): new €600 million notes and recent loss raise questio - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces €600 Million Notes Offering - GuruFocus
Becton Dickinson Euro Finance Issues €600 Million 3.855% Notes Due 2033 Guaranteed by BD - Minichart
Becton Dickinson subsidiary issues €600 million in 3.855% notes due 2033 - Investing.com Canada
Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt - TradingView
A Look at Becton Dickinson & Co (BDX) After 3.2% Gain -- GF Value $194.45 vs Price $146.95 - GuruFocus
Nebulizers - GlobeNewswire Inc.
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? - Barchart.com
BD Names Peter Menziuso to Lead $BD Interventional Business - citybiz
Becton, Dickinson and Company Appoints Peter Menziuso as Executive Vice President and President, Bd Interventional, Effective June 1, 2026 - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: Unveiling a 27.75% Potential Upside - DirectorsTalk Interviews
Becton Dickinson hikes profit outlook, names CFO - MSN
Becton Dickinson and Co stock (US0758871091): earnings beat and strategic focus keep medtech giant i - AD HOC NEWS
DNB Asset Management AS Has $22.28 Million Position in Becton, Dickinson and Company $BDX - MarketBeat
Northwestern Mutual Wealth Management Co. Increases Stock Position in Becton, Dickinson and Company $BDX - MarketBeat
Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target - Insider Monkey
Becton Dickinson & Co(BDX) Stock Options Chain | Quotes & News - Moomoo
Becton Dickinson's (NYSE:BDX) Strong Earnings Are Of Good Quality - Moomoo
Becton Dickinson and Co stock (US0758871091): Drops 2.4% to $143.97 after earnings - AD HOC NEWS
Jim Cramer Makes Big Claim About Beckton Dickinson (BDX) - Yahoo Finance
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Becton Dickinson Co Stock (BDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Polen Thomas E Jr | Chairman, CEO and President |
Jun 01 '26 |
Sale |
146.35 |
2,764 |
404,511 |
110,163 |
0.35%
2.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):